Mouse anti-Human C3/C3a Monoclonal Antibody | anti-C3/C3a antibody

C3/C3a, Human, mAb 2898

Cat. Num. AAA584432

• Reactivity: Human
• Applications: Western Blot
• Synonyms: C3/C3a; Monoclonal Antibody; Human; mAb 2898; Complement protein C3; anti-C3/C3a antibody

• Host: Mouse
• Reactivity: Human
• Clonality: Monoclonal
• Isotype: Mouse IgG1
• Form/Format: 1 ml (100 ug/ml) 0.2 um filtered antibody solution in PBS, containing 0.1% bovine serum albumin and 0.02% sodium azide.; For unit size 0.5 mg or larger: PBS only (concentration< 0.5mg/ml)

• Applicable Applications for anti-C3/C3a antibody: Immunoassay (IA), Western Blot (WB)
• Application Notes: Application Notes: W: A reduced sample treatment and SDS-PAGE was used. The band size is ~95 and 8.2 kDa for C3 and C3a respectively (Ref.1).; Application Use: For Western blotting, dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50.
• Immunogen: Peptide CARASHLGLA (last nine amino acids of C3a-desArg)
• Positive Control: Human plasma
• Preparation and Storage: Product should be stored at 4 degree C. Under recommended storage conditions, product is stable for at least one year. The exact expiry date is indicated on the label.

Related Product Information for anti-C3/C3a antibody

Product Description: The monoclonal antibody 2898 recognizes the C-terminus of human complement protein C3a. The antibody recognizes intact C3, C3a as well as C3a-desArg. C3 is the most abundant protein of the complement system with serum protein levels of about 1.3 mg/ml. The complement system is an important part of the humoral response in innate immunity, consisting of three different pathways. The third complement component, C3, is central to the classical, alternative and lectin pathways of complement activation. Activation products of the complement cascade contain neo-epitopes that are not present in the individual native components. Monoclonal antibodies detecting neo-epitopes have been used for direct quantification of activation at different steps in the complement cascade. The synthesis of C3 is tissue-specific and is modulated in response to a variety of stimulatory agents. An inherited deficiency of C3 predisposes the person to frequent assaults of bacterial infections. In ulcerative colitis, and idiopathic chronic inflammatory bowel disease, the deposition of C3 in the diseased mucosa has been reported. Proteolysis by certain enzymes results in the cleavage of C3 releasing C3a anaphylatoxin and C3b. C3a is a protein of 74 amino acids. C3a itself is very short-lived and in serum is cleaved rapidly into the more stable C3a-desArg (also called acylation stimulating protein, ASP). Therefore, measurement of C3a-desArg allows reliable conclusions about the level of complement activation in the test samples.
C3a is a mediator of local inflammatory processes. It induces smooth muscle contraction, increases vascular permeability, and causes histamine release from mast cells and basophilic leukocytes. C3a is involved in inflammatory reactions seen in gram-negative bacterial sepsis, trauma, ischemic heart disease, post-dialysis syndrome and a variety of autoimmune diseases.

References

1. Hartmann, H et al; Rapid quantification of C3a and C5a using a combination of chromatographic and immunoassay procedures. J Immunol Meth 1993, 166: 35 2. Smalley, D et al; Proteomic discovery of 21 proteins expressed in human plasma-derived but not platelet-derived microparticles. Thromb Haemost 2007, 97: 67